BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The firm will test gedatolisib as a first-line treatment in patients with HR-positive, HER2-negative advanced breast cancer who are endocrine therapy resistant.

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5, Comirnaty JN.1 and Comirnaty KP.2 may be administered concomitantly with a pneumococcal conjugated vaccine (PCV). an unadjuvanted ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Discover how CRISPR gene editing is creating personalized cancer therapies, enhancing immunotherapy, and offering new hope ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...